- Merck has opened two new facilities in Ireland and Germany with a combined investment of over €300 million.
- The projects form part of nearly €6 billion in global expansion, supporting innovation, sustainability, and supply chain security.
Merck has officially inaugurated two new facilities in Ireland and Germany as part of its global expansion strategy, representing a combined investment of more than €300 million.
In Blarney, Ireland, the company has invested €150 million in a life science filtration facility. The site will produce key materials used in the manufacture of vaccines, monoclonal antibodies, and emerging therapies. It is Merck’s first climate-neutral manufacturing facility and is expected to create more than 200 jobs by 2028.
In Darmstadt, Germany, Merck has opened a €160 million Healthcare Launch and Technology Centre. The centre is designed to bridge research and manufacturing, accelerating the delivery of therapies to patients. It has been developed with a strong focus on sustainability.
“These openings are just two of over 30 recently completed or ongoing investments in new or expanded sites across all business sectors and regions,” the company stated. In total, Merck is investing almost €6 billion worldwide to strengthen innovation, enhance supply security, and support local teams in serving patients and customers.
“This ongoing transformation of our global footprint will help us remain a science and technology leader for decades to come.”
CEO, Belén Garijo
